Ewing Sarcoma

Oncology·MeSH: Sarcoma, Ewing

Prevalence

0.5 / 100K

11 drugs in development·6 companies·12 clinical trials

Drug Pipeline by Phase

Phase 2(3)

Drug	Company
Elraglusib Injection	ACTUATE THERAPEUTICS, INC. (ACTU)
incb059872	Incyte Corp. (INCY)
ozekibart	Inhibrx Biosciences, Inc. (INBX)

Phase 1(7)

Drug	Company
INBRX-109	PTC THERAPEUTICS, INC. (PTCT)
INBRX-109	Merus N.V. (MRUS)
INBRX-109	IGM Biosciences, Inc. (IGMS)
leucovorin	Inhibrx Biosciences, Inc. (INBX)
Leucovorin	PTC THERAPEUTICS, INC. (PTCT)
pemetrexed	PTC THERAPEUTICS, INC. (PTCT)
trifluridine + tipiracil	Inhibrx Biosciences, Inc. (INBX)

Phase 2/Phase 3(1)

Drug	Company
inbrx-109	Inhibrx Biosciences, Inc. (INBX)

BioSniper tracks 11 drugs in development for Ewing Sarcoma across 6 companies.

There are 12 clinical trials targeting Ewing Sarcoma tracked by BioSniper.

The estimated prevalence of Ewing Sarcoma is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.